Brief: Cytodyn In Discussions With U.S. FDA, MHRA And Health Canada After Unblinding Its CD12 Trial Data For Severe-To-Critically Ill Covid-19 Patients

Cytodyn

22/02/2021 11:29

Feb 22 (Reuters) - Cytodyn Inc  CYDY.PK :
    * CYTODYN IN DISCUSSIONS WITH U.S. FDA, MHRA AND HEALTH
CANADA
AFTER UNBLINDING ITS CD12 TRIAL DATA FOR SEVERE-TO-CRITICALLY
ILL COVID-19 PATIENTS
    * CYTODYN IN DISCUSSIONS WITH U.S. FDA, MHRA AND HEALTH
CANADA
AFTER UNBLINDING ITS CD12 TRIAL DATA FOR SEVERE-TO-CRITICALLY
ILL COVID-19 PATIENTS
    * CYTODYN INC - EXPECTS TO RELEASE CD12 DATA AND COMPLETE
DISCUSSIONS WITH VARIOUS REGULATORY AGENCIES WITHIN 2 TO 3 WEEKS

Source text for Eikon:  ID:nGNX56JQxg 
Further company coverage:  CYDY.PK 

 ((Reuters.Briefs@thomsonreuters.com;))